Alprostadil: Dosing Protocols

Dosing Information#

Alprostadil is an FDA-approved medication available in multiple formulations for different clinical indications. The dosing information below reflects FDA-approved prescribing information and established clinical practice guidelines. All dosing should be prescribed and supervised by a licensed physician.

Intracavernosal Injection for Erectile Dysfunction#

Caverject (Alprostadil for Injection)#

Caverject is the most widely used intracavernosal formulation of alprostadil for erectile dysfunction. It is available as a lyophilized powder in 10 mcg, 20 mcg, and 40 mcg single-dose vials, as well as a prefilled dual-chamber injection system (Caverject Impulse).

Initial dose titration (mandatory in-office): The initial dose must be determined by a physician in the clinical setting, with the patient monitored for response and adverse effects. The titration protocol differs based on the etiology of erectile dysfunction:

• Vasculogenic, psychogenic, or mixed etiology ED:

  • Starting dose: 2.5 mcg
  • If partial response: increase to 5.0 mcg at the next visit (minimum 1-day interval)
  • Subsequent increments: increase by 5-10 mcg per visit until a dose is achieved that produces an erection suitable for intercourse lasting no longer than 1 hour
  • Typical dose range: 5-20 mcg
  • Maximum single dose: 40 mcg (Caverject) or 60 mcg (per some clinical protocols)

• Neurogenic etiology ED (e.g., spinal cord injury):

  • Starting dose: 1.25 mcg
  • If partial response: increase to 2.5 mcg, then 5.0 mcg at subsequent visits
  • Patients with neurogenic ED typically require lower doses
  • Typical dose range: 2.5-10 mcg

The dose-titration process typically requires 2-4 office visits. The physician should assess the onset, degree, and duration of the erectile response, as well as any adverse effects (particularly pain and signs of excessive response) at each visit.

Maintenance dosing:

• Use the lowest effective dose identified during titration
• Maximum frequency: 3 times per week
• Minimum interval: 24 hours between injections
• Injection sites should be alternated between the left and right corpora cavernosa and rotated within the dorsolateral aspect
• Patients should return for periodic evaluation (every 3-6 months initially) to assess for fibrosis and to re-evaluate dose appropriateness

Edex (Alprostadil Alfadex for Injection)#

Edex uses an alpha-cyclodextrin complex (alfadex) formulation that may provide improved stability and potentially reduced injection-site pain compared to Caverject. It is available in 10 mcg, 20 mcg, and 40 mcg single-dose cartridges.

Dosing protocol:

• Initial titration is identical to Caverject (starting at 2.5 mcg for vasculogenic/psychogenic ED, 1.25 mcg for neurogenic ED)
• Dose adjustments in 5-10 mcg increments
• Maximum recommended dose: 40 mcg
• Maximum frequency: 3 times per week with at least 24 hours between injections
• Reconstitute with 1.2 mL of provided diluent; inject within 24 hours of reconstitution

Injection Technique#

Proper injection technique is essential for both efficacy and safety. Patients should receive thorough training from their physician or trained healthcare professional before self-administering:

1. Preparation: Reconstitute the medication according to product instructions. Allow the solution to reach room temperature. Wash hands thoroughly.

2. Site selection: The injection is administered into the dorsolateral aspect of the proximal third of the penile shaft. Avoid the dorsal midline (to prevent dorsal nerve and vessel injury), the ventral surface (to avoid the urethra and corpus spongiosum), and any visible veins or areas of existing fibrosis.

3. Technique: Using a 27-gauge or 30-gauge 0.5-inch needle, hold the penis firmly against the thigh or abdomen to stabilize it. Insert the needle at a 90-degree angle directly into the corpus cavernosum. Inject the medication slowly over 5-10 seconds. Apply gentle pressure to the injection site for 2-3 minutes to minimize bruising and ensure drug distribution.

4. Post-injection: The patient should remain in the physician's office for monitoring during the titration phase. The physician should assess the response at 5-10 minute intervals. If erection occurs, the patient may be discharged with instructions to return or seek emergency care if the erection lasts longer than 4 hours.

Intraurethral Administration for Erectile Dysfunction#

MUSE (Medicated Urethral System for Erection)#

MUSE delivers alprostadil as a semi-solid pellet (suppository) that is placed into the urethra using a specialized single-use applicator. The drug is absorbed through the urethral mucosa and reaches the corpora cavernosa via vascular communications with the corpus spongiosum.

Available strengths: 125 mcg, 250 mcg, 500 mcg, and 1000 mcg pellets.

Initial dose titration (in-office):

• Starting dose: 125 or 250 mcg
• The patient should urinate before administration to lubricate the urethra
• Insert the applicator tip approximately 3 cm into the urethral meatus
• Depress the applicator button to release the pellet
• Remove the applicator and roll the penis firmly between the hands for 10-30 seconds to distribute the medication
• Assess response at 10-minute intervals for up to 30 minutes
• If inadequate response, the dose may be increased at the next visit (do not administer more than 2 pellets in 24 hours)

Maintenance dosing:

• Most patients respond to doses of 250-500 mcg
• Maximum single dose: 1000 mcg
• Maximum frequency: 2 administrations per 24-hour period
• Each administration should be separated by at least 24 hours (per the prescribing label; some clinicians allow twice-daily use)
• An optional ACTIS (Adjustable Constriction Therapeutic Infusion System) venous constriction band may be applied at the base of the penis after pellet insertion to improve drug retention and efficacy

Key differences from intracavernosal injection:

• Non-injection route -- no needles, which many patients prefer
• Generally lower efficacy than intracavernosal injection (43-65% vs. 70-87%)
• Lower risk of priapism (<1% vs. 1-4%)
• Higher incidence of urethral discomfort and minor bleeding
• Systemic absorption is greater, leading to more frequent hypotension/dizziness

Intravenous Infusion for Patent Ductus Arteriosus#

Prostin VR Pediatric (Alprostadil Injection)#

Intravenous alprostadil is used to maintain patency of the ductus arteriosus in neonates with ductal-dependent congenital heart defects pending surgical correction. This is a critical-care application administered exclusively in neonatal intensive care units.

Indications for PDA maintenance:

• Pulmonary atresia or severe pulmonary stenosis (ductal-dependent pulmonary blood flow)
• Transposition of the great arteries (ductal-dependent mixing)
• Critical coarctation of the aorta or interrupted aortic arch (ductal-dependent systemic blood flow)
• Tricuspid atresia and other complex single-ventricle physiology

Dosing protocol:

Preparation and administration:

• Dilute 500 mcg (1 mL) of Prostin VR Pediatric in 250 mL of 5% dextrose or 0.9% sodium chloride to achieve a concentration of 2 mcg/mL
• Alternative dilutions may be used based on fluid restriction requirements; more concentrated solutions (e.g., 20 mcg/mL) may be prepared for fluid-restricted neonates
• Administer via continuous infusion through a large peripheral vein, a central venous catheter, or directly into the opening of the ductus arteriosus via an umbilical arterial catheter positioned at the ductal opening
• Use a volumetric infusion pump for precise rate control
• Do not administer as a bolus injection

Monitoring requirements:

• Continuous cardiorespiratory monitoring (ECG, pulse oximetry, respiratory rate)
• Serial arterial blood gases (pre-ductal and post-ductal oxygen saturations in relevant defects)
• Blood pressure monitoring (arterial line preferred)
• Temperature monitoring (prostaglandin-mediated fever)
• Periodic assessment of ductal patency by echocardiography
• Monitor for apnea (intubation and mechanical ventilation capability must be immediately available)

Duration of therapy:

• Infusion is continued until definitive surgical repair or palliation is performed
• In most cases, this ranges from hours to several days
• Prolonged infusion (more than 5-7 days) increases the risk of cortical hyperostosis, gastric outlet obstruction, and other cumulative side effects
• When discontinued, the infusion rate should be gradually tapered rather than abruptly stopped, though clinical practice varies on this point

Intravenous Infusion for Critical Limb Ischemia (Off-Label)#

Alprostadil IV is used off-label in many countries (particularly in Europe and Japan) for the treatment of critical limb ischemia (CLI) in patients with severe peripheral arterial disease who are not candidates for revascularization.

Dosing protocols:

• Standard protocol: 40-60 mcg administered intravenously over 2 hours, once daily for 14-28 days
• Alternative protocol: 20 mcg administered over 2 hours twice daily
• Intra-arterial administration: 10-20 mcg administered directly into the affected limb's arterial supply over 60-120 minutes (requires interventional radiology expertise)

Preparation: Dilute the appropriate dose in 100-250 mL of 0.9% sodium chloride. The solution should be freshly prepared and used within 24 hours.

Monitoring: Blood pressure monitoring is required during and for 30 minutes after infusion. Heart rate should be monitored. Patients should remain recumbent or seated during infusion due to risk of orthostatic hypotension.

Clinical evidence: Several randomized controlled trials have demonstrated benefit of IV alprostadil in CLI, including improved rest pain scores, ulcer healing rates, and limb salvage at 6-12 months. The evidence is strongest for 4-week treatment courses. European Society of Cardiology/European Society of Vascular Surgery guidelines include alprostadil as a therapeutic option for CLI, though it is not FDA-approved for this indication in the United States.

Reconstitution and Preparation Details#

Caverject Powder for Injection#

• The Caverject Impulse system is a prefilled dual-chamber device that mixes the lyophilized powder with diluent when activated, simplifying preparation.
• After reconstitution, the solution should be visually inspected for particulate matter and discoloration. It should appear clear and colorless to slightly yellow.
• Do not refrigerate or freeze reconstituted solution (crystallization may occur).
• Discard any unused portion after 24 hours.

Edex (Alfadex Complex)#

• Reconstitute each cartridge with 1.2 mL of sodium chloride diluent provided in the kit.
• The alpha-cyclodextrin complex provides improved powder stability compared to unformulated alprostadil.
• Use reconstituted solution within 24 hours. Do not refrigerate.

Prostin VR Pediatric#

• Available as a sterile solution containing 500 mcg/mL in dehydrated alcohol.
• Must be diluted before administration. Standard dilution: 1 mL (500 mcg) in 250 mL of D5W or NS = 2 mcg/mL.
• Concentrated dilution for fluid-restricted neonates: 1 mL (500 mcg) in 25 mL = 20 mcg/mL (requires precise volumetric pump).
• Use plastic (polyolefin or PVC) infusion containers and tubing. Alprostadil may adsorb to some types of plastic, but this interaction is generally minimal at the recommended dilutions.

Storage Guidelines#

Special Population Dosing#

Hepatic Impairment#

No formal dose adjustments are published for hepatic impairment. However, since alprostadil is extensively metabolized by pulmonary and hepatic enzymes, patients with severe hepatic dysfunction may have altered clearance. Clinical monitoring and conservative dosing are recommended.

Renal Impairment#

Metabolites of alprostadil are primarily excreted renally. While no formal dose adjustments are recommended, metabolite accumulation in severe renal impairment is theoretically possible. The clinical significance is likely minimal given the short parent-compound half-life.

Elderly Patients#

No specific dose adjustments are required based on age alone. However, elderly patients may have increased sensitivity to the hypotensive effects and should be started at lower doses with careful titration.

Neonatal Considerations#

Neonatal dosing for PDA requires weight-based calculations and precise volumetric infusion control. Premature and low-birth-weight neonates (under 2 kg) have a higher incidence of apnea and may require lower starting doses (0.01-0.05 mcg/kg/min). Dosing adjustments should be guided by echocardiographic assessment of ductal patency and clinical response (oxygen saturation, systemic perfusion, blood pressure).

Related Reading#

• Alprostadil overview and research guide
• Alprostadil side effects profile
• Alprostadil research evidence